Here are the 10-K annual reports from HCW Biologics Inc. (HCWB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HCWB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCWB filings page.
HCW Biologics Inc. presents an in-depth business overview as a clinical-stage immunotherapy company focused on diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated dysplasia.
The company’s lead candidate HCW9302, an IL‑2 fusion protein, entered a Phase 1 trial in alopecia areata in November 2025, with two active U.S. sites and ongoing dose escalation to establish a recommended Phase 2 dose. Preclinical programs include the “Big BiTE” T‑cell engager HCW11‑018b for solid tumors and checkpoint fusion HCW11‑040 initially targeting bronchopulmonary dysplasia.
HCW highlights commercial‑ready reagents HCW9206 and HCW9201 for CAR‑T and NK cell manufacturing, extensive patent coverage for its TOBI and TRBC platforms, and out‑licensing deals with Wugen and Trimmune. As of March 25, 2026, common shares outstanding total 6,734,104, and non‑affiliate equity value was about $6.2 million as of June 30, 2025.